Sarcopenia

Oct 2, 2026

Regeneron's trevogrumab preserves 70% of muscle loss in obesity trials

Regeneron's trevogrumab prevents 70% of muscle loss in obesity patients treated with semaglutide, per Phase 2 COURAGE trial results.